Naloxegol US PMR CV Safety.

Study identifier:D3820R00008

ClinicalTrials.gov identifier:NCT02813356

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

United States Post-Marketing Observational Cardiovascular Safety Study in Patients taking Naloxegol

Medical condition

Opioid induced constipation

Phase

N/A

Healthy volunteers

No

Study drug

naloxegol, non-PAMORA

Sex

All

Actual Enrollment

8800

Study type

Observational

Age

N/A

Date

Study Start Date: 24 Jun 2016
Estimated Primary Completion Date: 31 Dec 2023
Estimated Study Completion Date: 31 Dec 2023

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria